High-dose Dual Therapy and Minocycline-containing Quadruple Therapy for Helicobacter pylori Infection

What this Trial Is About

This research aims to evaluate and compare treatments for people infected with Helicobacter pylori, a type of bacteria that can cause stomach problems. It is a Phase 4 multicenter prospective study including 200 patients confirmed positive for H. pylori by rapid urease test or 13C urea breath test. The study will follow ethical guidelines and obtain informed consent from all participants before enrollment. Researchers will assess factors such as antibiotic resistance, success rates, adverse reactions, and patient compliance during treatment. Participants will receive either a high-dose dual therapy or a quadruple therapy containing minocycline and other medications. The drugs studied include vonoprazan (a potassium competitive acid blocker), amoxicillin, bismuth potassium citrate (which protects the stomach lining and fights H. pylori), and a combination of minocycline and metronidazole antibiotics. All patients will undergo H. pylori culture and drug sensitivity testing to guide therapy. During the study, researchers will monitor the eradication rate of H. pylori six weeks after therapy completion. They will also observe adverse reactions and patient adherence to treatment. The study includes careful follow-up and assessments to measure treatment outcomes and antibiotic resistance impact. The total participation period and further follow-up details are guided by study protocols to ensure comprehensive evaluation of therapies.

High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection